Premium
Erratum: MET is a potential target for use in combination therapy with EGFR inhibition in triple‐negative/basal‐like breast cancer
Author(s) -
Yu Kim
Publication year - 2014
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.28964
Subject(s) - triple negative breast cancer , breast cancer , oncology , medicine , triple negative , basal (medicine) , cancer , cancer therapy , cancer research , insulin